Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 11/20 | 0.61 |
| ▸ | PIM1 | P11309 | 6/20 | 0.58 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.58 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | BAD | Q92934 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | LYN | P07948 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13057012 | 0.90 | LCK (0.63) | LCKPIM1PIM2CSNK2BCSNK2A1 | |
| SCHEMBL3790258 | 0.84 | LCK (0.55) | LCKPIM1PIM2CSNK2BCSNK2A1 | |
| SCHEMBL7981902 | 0.77 | LCK (1.00) | LCKPIM1PIM2CSNK2BCSNK2A1 | |
| SCHEMBL3789556 | 0.77 | PIM1 (0.56) | LCKPIM1PIM2CSNK2BCSNK2A1 | |
| SCHEMBL3789809 | 0.73 | PIM1 (0.70) | LCKPIM1PIM2CSNK2BCSNK2A1 | |
| SCHEMBL13056972 | 0.73 | PIM1 (0.56) | LCKPIM1PIM2CSNK2BCSNK2A1 | |
| SCHEMBL13056964 | 0.71 | PIM1 (0.50) | LCKPIM1PIM2CSNK2BCSNK2A1 | |
| SCHEMBL3790215 | 0.71 | PIM1 (0.50) | PIM1PIM2CSNK2BCSNK2A1MAPT | |
| SCHEMBL7980884 | 0.67 | LCK (1.00) | LCK | |
| SCHEMBL12768514 | 0.67 | PIM1 (0.61) | PIM1PIM2CSNK2BCSNK2A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135571-A1 | NOVEL PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | PIM2, PIM1, PIM3 | LCK 49/4885PIM1 2/4885PIM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.